Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

Separately, Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Friday, March 17th.

Marinus Pharmaceuticals (MRNS) traded down 2.16% on Friday, reaching $1.36. 294,067 shares of the company were exchanged. The stock has a 50-day moving average price of $1.28 and a 200 day moving average price of $1.30. The stock’s market capitalization is $30.49 million. Marinus Pharmaceuticals has a 52 week low of $0.82 and a 52 week high of $2.73.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Monday, May 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.06. Analysts forecast that Marinus Pharmaceuticals will post ($1.00) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

Several institutional investors have recently made changes to their positions in the stock. Nexthera Capital LP bought a new position in shares of Marinus Pharmaceuticals during the first quarter worth about $1,416,000. Granite Point Capital Management L.P. bought a new position in shares of Marinus Pharmaceuticals during the first quarter worth about $1,372,000. Jennison Associates LLC bought a new position in shares of Marinus Pharmaceuticals during the first quarter worth about $690,000. Finally, KCG Holdings Inc. increased its position in shares of Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 14,692 shares in the last quarter. Institutional investors and hedge funds own 32.69% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.